When pressed for 2025 expectations, Verona believed $254 million in revenues was a fair estimate. Critically, Verona expects ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) ...

Verona Pharma is a biopharmaceutical company ... of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre TM (ensifentrine) is the Company’s first commercial product ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

If you need financial support to pay for Ohtuvayre or help understanding your insurance coverage, assistance is available. For example: A program called Verona Pathway Plus is available for Ohtuvayre.

If you need financial support to pay for Ohtuvayre, or if you need help understanding your insurance coverage, help is available. For example: A program called Verona Pathway Plus is available for ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: A live webcast will be available on the Events and Presentations link on the Investors page of the ...